Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,825.00    -25.00 (-0.51%)
Bid:
4,750.00
Ask:
4,900.00
Spread: 150.00 (3.158%)
Market Cap: £323.04m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Acquisition

19 Mar 2010 07:00

RNS Number : 8335I
Judges Scientific PLC
19 March 2010
 



19 March 2010

 

JUDGES SCIENTIFIC plc

("Judges Scientific", "Judges" or the "Company")

 

ACQUISITION OF SIRCAL INSTRUMENTS (UK) LIMITED

 

Judges Scientific, the parent company of a group that specialises in the design, manufacture and sale of scientific instruments, announces that its wholly-owned subsidiary, Fire Testing Technology Limited ("FTT"), has today completed the acquisition of the entire issued share capital of Sircal Instruments (UK) Limited ("Sircal") for a consideration of £1 million, payable in cash. An additional payment will be made to reflect the working capital available at completion in excess of the ongoing requirements of the business. Such payment is expected by Judges to be more than covered by the cash inherited at completion.

 

Sircal designs, manufactures and distributes rare gas purifiers for use in metals analysis utilising the Arc Spark spectrometry technique. This technique provides qualitative and quantitative analysis of a metallic sample. The process does not require complicated sample preparation and is widely used in the metals industry. When accurate measurements are required, the process must be carried out in an environment free from the type of contaminants that would affect the performance of the metal; the test is therefore conducted in an atmosphere of rare gas (usually argon) that is itself sufficiently free from contamination.  The function of the purifier is to achieve the required rare gas purity.

 

The principal markets for Arc Spark spectrometry relate to the production of speciality steel, cast iron, aluminium and other non-ferrous metals. These are the markets served by Sircal, directly or through OEM customers who manufacture spectrometers. In contrast to the majority of Judges' existing operations, Sircal is largely reliant on the private sector. The vast majority of Sircal's production is exported, as is the case with the other businesses in the Judges group. Judges believes the company to be a clear world leader in the market for purifiers used in metals analysis. Sircal's revenues include a significant element of consumables (approximately 30% in the last financial year).

 

The two vendors were among the founders of Sircal in 1981 and since 2004 have been its only employees. It has been agreed that they will assist Judges during a three-month transition period while the business is transferred to FTT's premises, where it will be operated by the FTT team. Judges Scientific will not assume responsibility for Sircal's existing premises. The Board of Judges believes that risk is reduced in such an acquisition where the purchaser does not inherit responsibility for staff or premises.

 

Sircal's unaudited accounts for the year ended 30 September 2009 show sales of £785,000 on which the company generated operating profits of £337,000. Net tangible assets at 30 September 2009 amounted to £423,000, including £458,000 of cash and cash equivalents. Sircal's operating profits figure of £337,000 reflects the way the business has been operated historically; the Board of Judges believes that, had the business been owned by the Company during that period, it would have generated a contribution in the order of £270,000. The Board expects the acquisition to be earnings-enhancing in the current year.

 

The Bank of Scotland has made available to Judges a £1 million extension to the £3 million term loan which was arranged in June 2009 to finance the acquisition of Quorum Technologies Limited and to refinance the Company's outstanding borrowings at that time. In addition, a £500,000 overdraft facility continues to be available to the Company.

 

Alex Hambro, Chairman of Judges, commented: "I am delighted that we have purchased another niche instrument business and that we have been able to do so without issuing shares. We regard our level of indebtedness as prudent, Sircal comes without the usual fixed cost commitments and the nature of its customer base will serve to moderate the Group's current bias towards public sector markets. This acquisition should prove earnings-enhancing in the current year, while providing an unusually low level of added risk".

 

Enquiries:

 

David Cicurel, CEO, Judges Scientific: Tel: 01342 323 600

 

Pascal Keane, Shore Capital: Tel: 020 7408 4090

 

Melvyn Marckus, Cardew Group: Tel: 07775 896 491

 

Web sites:

 

Judges Scientific: www.judges.uk.com

 

Sircal: www.sircal.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUWRWRRUAOAAR
Date   Source Headline
7th Jan 20161:53 pmRNSDirector/PDMR Shareholding
9th Dec 20154:32 pmRNSDirector/PDMR Shareholding
1st Dec 20157:00 amRNSTotal Voting Rights
16th Nov 201510:58 amRNSBlocklisting Interim Review
6th Nov 20154:57 pmRNSDirector/PDMR Shareholding
2nd Nov 20157:00 amRNSTotal Voting Rights
21st Oct 201512:00 pmRNSNew option schemes, Director/PDMR Shareholding
16th Oct 20153:24 pmRNSDirector/PDMR Shareholding
8th Oct 20155:08 pmRNSDirector/PDMR Shareholding
7th Oct 20152:10 pmRNSDirector/PDMR Shareholding
1st Oct 20157:00 amRNSTotal Voting Rights
28th Sep 20156:00 pmRNSDirector/PDMR Shareholding
25th Sep 20157:00 amRNSHalf Yearly Report
14th Sep 20155:29 pmRNSDirector/PDMR Shareholding
1st Sep 20157:03 amRNSTotal Voting Rights
7th Aug 20157:00 amRNSDirector/PDMR Shareholding
24th Jul 20155:21 pmRNSDirector/PDMR Shareholding and Notice of Results
23rd Jul 20157:00 amRNSTrading Statement
8th Jul 20155:24 pmRNSDirector/PDMR Shareholding
1st Jul 20157:00 amRNSTotal Voting Rights
8th Jun 20153:00 pmRNSDirector/PDMR Shareholding
1st Jun 20157:00 amRNSTotal Voting Rights
27th May 20152:18 pmRNSResult of AGM
22nd May 20157:00 amRNSPAYMENT OF DEFERRED CONSIDERATION
13th May 20152:17 pmRNSBlocklisting Application
6th May 20153:35 pmRNSDirector/PDMR Shareholding
29th Apr 201510:40 amRNSExercise of Options
21st Apr 201511:15 amRNSExercise of Options
16th Apr 20151:46 pmRNSIssue of Equity
9th Apr 20154:22 pmRNSDirector/PDMR Shareholding
8th Apr 20155:02 pmRNSDirector/PDMR Shareholding
31st Mar 20155:49 pmRNSDirector/PDMR Shareholding
31st Mar 20157:00 amRNSDirector/PDMR Shareholding
27th Mar 20157:00 amRNSFinal Results
11th Mar 20157:00 amRNSDirector/PDMR Shareholding
9th Mar 201512:10 pmRNSNotice of Results
3rd Mar 20157:00 amRNSAppointment of Director and Board transition
10th Feb 20154:26 pmRNSExercise of Options
9th Feb 20155:06 pmRNSDirector/PDMR Shareholding
4th Feb 20155:56 pmRNSHolding(s) in Company
4th Feb 201511:26 amRNSHolding(s) in Company
23rd Jan 201511:45 amRNSDirector/PDMR Shareholding and Exercise of Options
22nd Jan 20154:26 pmRNSDirector/PDMR Shareholding
22nd Jan 20157:00 amRNSAcquisition
20th Jan 20157:00 amRNSTrading Statement
7th Jan 201511:29 amRNSDirector/PDMR Shareholding
23rd Dec 20142:10 pmRNSNew Term Loan and Acquisition Facility
11th Nov 20143:31 pmRNSDirector/PDMR Shareholding
16th Oct 20149:42 amRNSReplacement: Director/PDMR Shareholding
8th Oct 20142:31 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.